Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sepantronium Bromide in Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma
NCT05263583Phase 2Completed
- Sponsor
- Cothera Bioscience
- Start
- Dec 2022
- Primary completion
- Feb 2025
- Modality
- Classical Binding Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of sepantronium in high grade B-cell lymphoma (HGBCL) (3 cohorts), sponsored by Cothera Bioscience. Primary endpoint: Safety and tolerability and recommended Phase 2 dose at 6 months. Started Dec 2022; status: completed.
02
Drugs
sepantronium
03
Conditions
high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT05263583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263583.